4D Molecular Therapeutics (FDMT) Cash from Investing Activities Growth (1y) (2021 - 2026)
4D Molecular Therapeutics (FDMT) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - | 115.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 115.63% |
| Dec 31, 2025 | -1,925.29% |
| Sep 30, 2025 | -34.88% |
| Jun 30, 2025 | 81.16% |
| Mar 31, 2025 | 112.14% |
| Dec 31, 2024 | 205.64% |
| Sep 30, 2024 | -8.94% |
| Jun 30, 2024 | -249.20% |
| Mar 31, 2024 | -710.38% |
| Dec 31, 2023 | 81.32% |
| Sep 30, 2023 | 95.05% |
| Jun 30, 2023 | -14.23% |
| Mar 31, 2023 | 179.71% |
| Dec 31, 2022 | -10.80% |
| Sep 30, 2022 | 111.06% |
| Jun 30, 2022 | 7,897.56% |
| Mar 31, 2022 | -8,328.35% |
| Dec 31, 2021 | -6,256.50% |
| Sep 30, 2021 | -39,930.95% |
| Jun 30, 2021 | -514.17% |